TNFRSF25 and hepatocellular carcinoma: Studies have demonstrated that the expression of DR3 in the hepatocarcinoma cell lines SMMC-7721 and HepG2 was increased compared to that of normal liver cells; furthermore, the anti-cancer drug lupeol, was shown to have potential in decreasing DR3 expression levels in hepatocellular carcinoma cells (43).